Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for Outset Medical (OM) over the last 7 years, with Q4 2025 value amounting to $881000.0.

  • Outset Medical's Depreciation & Amortization (CF) fell 3734.0% to $881000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $4.3 million, marking a year-over-year decrease of 2421.44%. This contributed to the annual value of $4.3 million for FY2025, which is 2421.44% down from last year.
  • As of Q4 2025, Outset Medical's Depreciation & Amortization (CF) stood at $881000.0, which was down 3734.0% from $1.0 million recorded in Q3 2025.
  • Outset Medical's Depreciation & Amortization (CF)'s 5-year high stood at $1.5 million during Q2 2023, with a 5-year trough of $881000.0 in Q4 2025.
  • Its 5-year average for Depreciation & Amortization (CF) is $1.3 million, with a median of $1.3 million in 2021.
  • In the last 5 years, Outset Medical's Depreciation & Amortization (CF) surged by 30852.46% in 2021 and then tumbled by 3734.0% in 2025.
  • Quarter analysis of 5 years shows Outset Medical's Depreciation & Amortization (CF) stood at $1.3 million in 2021, then dropped by 2.08% to $1.3 million in 2022, then grew by 13.95% to $1.4 million in 2023, then dropped by 2.77% to $1.4 million in 2024, then crashed by 37.34% to $881000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $881000.0 in Q4 2025, compared to $1.0 million in Q3 2025 and $1.2 million in Q2 2025.